A composition comprising: a racetam; an extract of Mucuna Pruriens; S-Adenosyl methionine; and caffeine; useful for improvement of alertness, physical endurance, sleep patterns, memory, perceptual acuity, and/or for increasing energy.

A composition comprising: a racetam; an extract of Mucuna Pruriens; S-Adenosyl methionine; and caffeine; useful for improvement of alertness, physical endurance, sleep patterns, memory, perceptual acuity, and/or for increasing energy.

A method of treating sleep apnea is provided. The method including the step of administering 12.5 mg to 25.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 5.0 mg to 100.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.

A method of treating sleep apnea is provided. The method including the step of administering 12.5 mg to 25.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 5.0 mg to 100.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.

A method of treating sleep apnea is provided. The method including the step of administering 12.5 mg to 25.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 5.0 mg to 100.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.

Provided is a composition for oral administration, which can include a combination of an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus, and at least one of a cannabis oil or a cannabinoid and optionally, a material comprising a surfactant or an oil, and wherein the composition has a reduced undesirable taste compared with the same composition lacking the extracellular portion. Also provided is a method for reducing undesirable tastes in a composition comprising a cannabinoid or cannabis oil for oral administration, which include adding an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus to the cannabinoid-containing or cannabis oil-containing product for oral administration in an amount sufficient to reduce at least one undesirable taste in the composition.

Provided is a composition for oral administration, which can include a combination of an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus, and at least one of a cannabis oil or a cannabinoid and optionally, a material comprising a surfactant or an oil, and wherein the composition has a reduced undesirable taste compared with the same composition lacking the extracellular portion. Also provided is a method for reducing undesirable tastes in a composition comprising a cannabinoid or cannabis oil for oral administration, which include adding an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus to the cannabinoid-containing or cannabis oil-containing product for oral administration in an amount sufficient to reduce at least one undesirable taste in the composition.

Provided is a composition for oral administration, which can include a combination of an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus, and at least one of a cannabis oil or a cannabinoid and optionally, a material comprising a surfactant or an oil, and wherein the composition has a reduced undesirable taste compared with the same composition lacking the extracellular portion. Also provided is a method for reducing undesirable tastes in a composition comprising a cannabinoid or cannabis oil for oral administration, which include adding an extracellular portion from a mycelial aqueous culture comprising a filamentous fungus to the cannabinoid-containing or cannabis oil-containing product for oral administration in an amount sufficient to reduce at least one undesirable taste in the composition.

The invention relates to the field of health food technologies, and particularly to a composition and an application thereof in preparing a product for protecting mitochondria. The invention provides a composition, the raw materials of which include Haematococcus pluvialis, Lycium ruthenicum, Cordyceps militaris and nicotinamide. The composition has the effects of improving an oxidative stress level under a mitochondrial dysfunction and delaying mitochondrion-related aging. Compared with a single constituent, constituents in the composition cooperate with each other to produce a synergistic effect, which significantly improves an effect of protecting a mitochondrial function.

The invention relates to the field of health food technologies, and particularly to a composition and an application thereof in preparing a product for protecting mitochondria. The invention provides a composition, the raw materials of which include Haematococcus pluvialis, Lycium ruthenicum, Cordyceps militaris and nicotinamide. The composition has the effects of improving an oxidative stress level under a mitochondrial dysfunction and delaying mitochondrion-related aging. Compared with a single constituent, constituents in the composition cooperate with each other to produce a synergistic effect, which significantly improves an effect of protecting a mitochondrial function.